billHR2667Event Monday, April 7, 2025Analyzed

Flexible Savings Arrangements for a Healthy Robust America Act

Bullish
Impact5/10

Summary

HR2667 would allow FSA/HRA funds to roll tax-free into HSAs upon HDHP enrollment, expanding the addressable market for HSA administrators and HDHP issuers. The bill is at early stage (referred to Ways and Means, no appropriations). Recent 30-day gains for UNH (+36.1%), HUM (+40.2%) and CVS (+16.4%) are driven by broader sector momentum, not this bill alone. Near-term market impact is limited due to early legislative stage.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR2667 would allow FSA/HRA funds to roll tax-free into HSAs upon HDHP enrollment, expanding HSA asset inflows by removing the use-it-or-lose-it barrier.
  • 2.The bill is in early stage (Ways and Means referral, 2 cosponsors) with low near-term passage probability; no companion Senate bill exists.
  • 3.Recent 30-day rallies in UNH (+36%), HUM (+40%), and CVS (+16%) are driven by broader sector momentum, not HR2667.
  • 4.Structural beneficiaries are HSA administrators (Optum/UNH) and HDHP issuers (UNH, CVS, HUM), but impact is contingent on passage.
  • 5.Revenue impact is modest — if passed, estimated $15M-$60M annually across the sector from expanded HSA contributions and HDHP enrollment.

Market Implications

The bill alone has not moved stocks. UNH ($368.22) has rallied 36% in 30 days, HUM ($243.09) 40%, and CVS ($83.57) 16% — all trading at or near their 52-week highs. These moves correlate with broader healthcare sector momentum (Medicare Advantage rate finalization, strong earnings cycles) rather than tax policy expectations. If HR2667 gains legislative traction — e.g., committee markup, addition of bipartisan cosponsors, or folding into year-end tax extenders — HSA administrators and HDHP-centric insurers would see incremental upside. Near-term, the major managed care names are already pricing in substantial sector optimism; HR2667 is not a catalyst for current levels.

Full Analysis

On April 7, 2025, Rep. Bean (R-FL) introduced HR2667, the Flexible Savings Arrangements for a Healthy Robust America Act, with 2 cosponsors (Reps. Panetta (D-CA) and Crenshaw (R-TX)). The bill was referred to the House Committee on Ways and Means, where it remains. This is an early-stage authorization bill with no appropriations — it authorizes a change in tax treatment, not government spending. The bill amends Internal Revenue Code Sections 106(e)(2) and 223(b)(4) to allow a one-time qualified HSA distribution from a health FSA or HRA directly into an HSA, capped at the Sec. 125(i)(1) limit (2026: $1,700 for self-only, $3,400 for family coverage). This eliminates the current 'use-it-or-lose-it' barrier that discourages FSA holders from switching to HDHPs, effectively converting trapped FSA balances into HSA funding. The structural winners are HSA administrators and HDHP issuers. The largest HSA administrator is Optum Bank (UnitedHealth Group, $UNH), which held ~$17 billion in HSA assets as of 2025. HSA Bank (Webster Financial, $WBS) and Fidelity ($FNF) are also major players. Among HDHP issuers, UnitedHealthcare ($UNH), Aetna/CVS ($CVS), Humana, and Blue Cross Blue Shield affiliates stand to benefit from increased HDHP adoption. Recent market data shows strong 30-day returns for UNH (+36.1% to $368.22), HUM (+40.2% to $243.09), and CVS (+16.4% to $83.57). These movements are significantly larger than the 30th-percentile sector gains, indicating broader momentum in healthcare stocks — likely tied to Medicare Advantage rate announcements, earnings reports, and general sector rotation — rather than price action driven by this early-stage bill. No stock-specific news links HR2667 to the observed price moves. Legislative timeline: The bill must clear Ways and Means (chaired by Rep. Jason Smith, R-MO), pass the House, then clear the Senate Finance Committee and full Senate. With only 2 cosponsors and a 2025 introduction, this bill is in early, low-probability territory. No companion bill has been introduced in the Senate. The 119th Congress runs through January 2027, providing a two-year window, but the bill faces significant competition for legislative attention. Actual enactment is a low-probability event absent a larger healthcare tax package.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Strong

Multiple independent sources confirm this signal’s market thesis

Confirmed by:
$$UNH▲ Bullish
Est. $15.0M$50.0M revenue impact

What the bill does

Tax code amendment allowing pre-tax FSA/HRA funds to roll directly into an HSA upon HDHP enrollment

Who must act

Employers offering both an FSA/HRA and an HDHP with an HSA option

What happens

Increased pool of pre-tax dollars eligible for HSA contributions; removes the 'use-it-or-lose-it' barrier for FSA holders transitioning to HDHPs, expanding the annual addressable HSA contribution flow by an estimated $1,000-$2,000 per converting employee

Stock impact

UnitedHealth's Optum Bank HSA business and its UnitedHealthcare HDHP offerings benefit from higher HSA asset inflows (management fees) and higher HDHP premium volume. Optum's HSA administration revenue grows proportionally to new HSA contributions. UNH is the largest HSA administrator by deposits.

$$CVS▲ Bullish
Est. $10.0M$60.0M revenue impact

What the bill does

Tax code amendment allowing pre-tax FSA/HRA funds to roll directly into an HSA upon HDHP enrollment

Who must act

Employers and consumers purchasing HDHPs from Aetna (CVS's health insurance subsidiary)

What happens

Higher HDHP enrollment through Aetna increases medical premium revenue and pharmacy benefit claim volume through CVS Caremark (PBM), both of which benefit when a new member selects an Aetna HDHP paired with an HSA

Stock impact

CVS's Aetna segment sells HDHPs under its commercial product line. Any policy that expands HDHP adoption benefits Aetna's commercial enrollment. Additionally, CVS Caremark processes prescriptions for these members. The bill's effect is structural but modest relative to CVS's $350B+ revenue base.

Market Impact Score

5/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

presidential_memorandumApr 20, 2026

Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Development, Manufacturing, and Deployment of Large-Scale Energy and Energy‑Related Infrastructure

This presidential memorandum invokes Section 303 of the Defense Production Act (DPA) to accelerate the development, manufacturing, and deployment of large-scale energy and energy-related infrastructure. It authorizes the Secretary of Energy to make necessary purchases, commitments, and financial instruments to expand domestic capabilities in this sector, citing a national energy emergency and the need to avert an industrial resource shortfall.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.